Linda Cook
Professor
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (39)
Year:
2025
Background: The prognostic relationship between diet and endometrial cancer survival remains largely unknown. We sought to determine pre- and post-diagnosis dietary composition, glycemic load (GL), inflammatory potential (dietary inflammatory index) and quality [Canadian Healthy Eating Index (C-HEI) 2005] associations with disease-free (DFS) and overall survival (OS) among endometrial cancer survivors. In addition, we assessed associations between dietary changes with OS and explored obesity/physical activity effect modification. Methods: Survivors, diagnosed in Alberta, Canada between 2002 and 2006, completed past-year, food-frequency questionnaires at-diagnosis ( n = 503) and 3-year follow-up ( n = 395). Participants were followed to death or January 2022. Cox proportional regression estimated HR [95% confidence intervals (CI)] for dietary survival associations. Results: During 16.9 median years of follow-up, 138 participants had a DFS event and 120 died. Lower pre-diagnosis GL (HR T1vsT3 , 0.49; 95% CI, 0.25–0.97) and greater post-diagnosis energy intakes (EI) from total- and monounsaturated-fat (HR T3vsT1 , 0.48; 95% CI, 0.26–0.87) were associated with better OS. Higher pre-diagnosis C-HEI, less inflammatory diets and lower added sugar intakes were nonlinearly associated with better DFS. Consistently low pre- to post-diagnosis EI from carbohydrates and total-fats were associated with better (HR, 0.36; 95% CI, 0.18–0.72) and worse (HR, 2.26; 95% CI, 1.21–4.20) OS, respectively. Decreased pre- to post-diagnosis C-HEI was associated with worse OS. In stratified analysis, healthy diets were most beneficial for survivors with obesity and physical inactivity. Conclusions: Adherence to higher quality dietary patterns were associated with better survival. Impact: Our study provides novel evidence that both pre- and post-diagnosis diet are important prognostic factors for endometrial cancer survivors. Post-diagnosis survival associations with diet composition and quality highlight the potential for future interventions.
Year:
2025
Disease-free and overall survival outcomes for pre-diagnosis (n=503) and post-diagnosis (n=395) standard servings of major food groups in Canada's Food Guide in the Alberta Endometrial Cancer Cohort, 2002–2022
Year:
2025
We examined associations between modifiable and nonmodifiable cancer-related risk factors measured at endometrial cancer diagnosis and during early survivorship (~3 years postdiagnosis) with second primary cancer (SPC) risk among 533 endometrial cancer survivors in the Alberta Endometrial Cancer Cohort using Fine and Gray subdistribution hazard models. During a median follow-up of 16.7 years (IQR, 12.2-17.9), 89 (17%) participants developed an SPC; breast (29%), colorectal (13%), and lung (12%) cancers were the most common. Dietary glycemic load before endometrial cancer diagnosis (≥90.4 vs < 90.4 g/day: subhazard ratio [sHR] = 1.71; 95% CI, 1.09-2.69), as well as older age (≥60 vs < 60 years: sHR = 2.48; 95% CI, 1.34-4.62) and alcohol intake (≥2 drinks/week vs none: sHR = 3.81; 95% CI, 1.55-9.31) during early survivorship, were associated with increased SPC risk. Additionally, reductions in alcohol consumption from prediagnosis to early survivorship significantly reduced SPC risk (sHR = 0.34; 95% CI, 0.14-0.82). With 1 in 6 survivors developing an SPC, further investigation of SPC risk factors and targeted surveillance options for high-risk survivors could improve long-term health outcomes in this population. Reductions in dietary glycemic load and alcohol intake from prediagnosis to early survivorship showed promising risk reductions for SPCs and could be important modifiable risk factors to target among endometrial cancer survivors. This article is part of a Special Collection on Gynecological Cancer.
Year:
2024
Characterization of HGSC with co-loss of RB1 and BRCA . A, GSEA indicating up- and downregulated pathways in tumors according to BRCA and RB1 status. RB1 -alt, RB1 altered; RB1 -wt, RB1 wild-type. B, Boxplots comparing GSVA pathway enrichment scores of the cGAS-STING and Toll-like receptor signaling pathways between molecular subgroups; points represent each sample, boxes show the interquartile range (25th–75th percentiles), central lines indicate the median, and whiskers show the smallest/largest values within 1.5 times the interquartile range. Colored boxes with black points indicate the HRD and/or RB1 altered groups, whereas the gray boxes with gray points indicate the HRP and RB1 wild-type group. P values were calculated using a two-sided Mann–Whitney-Wilcoxon test. Benjamini–Hochberg adjusted P values are shown above each pairwise comparison (*, P P P ≥ 0.05). C, Bubble plot summary of HLA gene expression comparisons using DESeq2 between HGSC tumors grouped by HRD and/or RB1 status as shown. The size of the bubbles corresponds to the negative log 10 Benjamini–Hochberg adjusted P value ( P adj ) and only values with P adj ≤ 0.1 are shown. The color and intensity correspond to the log 2 fold change. Genes are grouped by their classes. D, Proportion of TILs in HGSC tumors grouped by RB1 protein expression and BRCA germline status. χ 2 P value is indicated. E, Proportion of tumors classified as each HGSC molecular subtype ( 13 ) grouped by RB1 expression and BRCA germline status. χ 2 P value is indicated. C4.DIF, C4/differentiated subtype; C2.IMM, C2/immunoreactive subtype; C1.MES, C1/mesenchymal subtype; C5.PRO, C5/proliferative subtype.
Year:
2024
Sensitivity to therapeutic agents in BRCA1 -altered cell lines with RB1 knockout. A, RB1 was knocked out using CRISPR/Cas9 in three patient-derived Australian Ovarian Cancer Study (AOCS) HGSC cell lines with either wild-type or altered BRCA1 ( BRCA1 var) background. Representative Western Blots show protein levels of RB1 and phosphorylated RB1 (pRB1) compared with GAPDH loading control in single-cell cloned, homozygous RB1 wild-type (WT) and knockout (KO) colonies in comparison with heterogeneous populations with a scramble single guide RNA (sgRNA). Independent blots were used for RB1 and pRB1. B, Cell viability was compared between RB1 WT and KO clones following treatment with cisplatin (72 h), paclitaxel (72 h), or olaparib (120 h). Nonlinear regression drug curves are shown; P values are shown in Supplementary Table S18 ( n = 3). Error bars indicate ± SEM; for some values, error bars are shorter than the symbols and thus are not visible. C, Proportion of surviving colonies following 16 days of treatment with cisplatin, paclitaxel, or a combination of both (Cis/Pac; with half of the IC50 determined per drug and cell line respectively) relative to DMF vehicle control ( n = 3 replicates). Data are presented as mean ± SEM. Mean values were compared by Student’s t test (ns, not significant; *, P P
Year:
2024
Supplementary Table S17. Half maximum inhibitory concentrations (IC50) for cisplatin (72 hours), paclitaxel (72 hours), or olaparib (120 hours) in HGSC cell lines with innate RB1 and/or BRCA1 alterations.
Year:
2024
Genomic landscape of high-grade serous ovarian tumors with co-occurring BRCA and RB1 alterations. A, Pathogenic germline and somatic alterations in HR and DNA repair genes detected by whole-genome sequencing and DNA methylation analysis of 126 primary HGSC samples ( 27 ) are shown, as well as alterations in immune genes and CCNE1 . Samples are grouped by HR and RB1 status. Bars at the top indicate the number of alterations in each listed gene per patient. Patients are annotated with survival group (LTS, long-term survivor, OS > 10 years; MTS, mid-term survivor, OS 2–10 years; STS, short-term survivor, OS 41 ) scores, and the proportion of structural variant (SV) type (DEL, deletion; DUP, duplication; INV, inversion; ITX, intra-chromosomal translocation). B, Kaplan–Meier estimates of progression-free survival (left) and overall survival (right) of patients according to HR status ( BRCA1 -type HRD; BRCA2 -type HRD; or HRP tumors) and RB1 status (altered vs. wild-type).
Year:
2024
Sensitivity to therapeutic agents in BRCA1 -altered cell lines with RB1 knockout. A, RB1 was knocked out using CRISPR/Cas9 in three patient-derived Australian Ovarian Cancer Study (AOCS) HGSC cell lines with either wild-type or altered BRCA1 ( BRCA1 var) background. Representative Western Blots show protein levels of RB1 and phosphorylated RB1 (pRB1) compared with GAPDH loading control in single-cell cloned, homozygous RB1 wild-type (WT) and knockout (KO) colonies in comparison with heterogeneous populations with a scramble single guide RNA (sgRNA). Independent blots were used for RB1 and pRB1. B, Cell viability was compared between RB1 WT and KO clones following treatment with cisplatin (72 h), paclitaxel (72 h), or olaparib (120 h). Nonlinear regression drug curves are shown; P values are shown in Supplementary Table S18 ( n = 3). Error bars indicate ± SEM; for some values, error bars are shorter than the symbols and thus are not visible. C, Proportion of surviving colonies following 16 days of treatment with cisplatin, paclitaxel, or a combination of both (Cis/Pac; with half of the IC50 determined per drug and cell line respectively) relative to DMF vehicle control ( n = 3 replicates). Data are presented as mean ± SEM. Mean values were compared by Student’s t test (ns, not significant; *, P P
Year:
2024
Expression of RB1 and survival associations across ovarian cancer histotypes. A, Representative images of IHC detection of RB1 expression in ovarian carcinoma tissues, showing examples of the three most common expression patterns: retained, lost, and subclonal loss. B, Proportion of patients with loss or retention of RB1 protein expression in tumor samples by ovarian cancer histotypes. χ 2 P value reported for difference in proportions across all histotypes. CCOC, clear cell ovarian cancer; LGSC, low-grade serous carcinoma; MOC, mucinous ovarian cancer. C, Boxplots show RB1 mRNA expression (NanoString) by RB1 protein expression status; lines indicate median and whiskers show range (Mann–Whitney test P value reported). Kaplan–Meier analysis of OS in patients diagnosed with HGSC ( D ) and ENOC ( E ) stratified by tumor RB1 expression. F, Frequency of germline BRCA wild-type (g BRCA wt) and germline BRCA pathogenic variants (g BRCA var) in patients with HGSC stratified by RB1 protein expression. χ 2 P value is reported. G, Kaplan–Meier estimates of overall survival in patients with HGSC by combined germline BRCA and tumor RB1 expression status.
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2023
Collaborators (72)
Madeleine Shackleford
Professional Research Assistant
University of Colorado Anschutz Medical Campus
Junxiao Hu
Assistant Professor
University of Colorado Anschutz Medical Campus
Carlo La Vecchia
Professor of Epidemiology
Università degli Studi di Torino
Elizabeth Christie
Peter MacCallum Cancer Institute
Timothy Budden
Lecturer
University of Liverpool
Anna E. Prizment
Faculty, Associate Professor
University of Minnesota
Beth Karlan
Vice Chair
University of California, Los Angeles
Xiao‐Ou Shu
Vanderbilt University Medical Center
Anna Jakubowska
Head
Pomeranian Medical University
Lynne Wilkens
Professor
University of Hawaii at Manoa
Sven Sandin
Associate Professor
Karolinska Institutet
Carlotta Sacerdote
Docenti di ruolo di Ia fascia
Università degli Studi del Piemonte Orientale Amedeo Avogadro
Anthony Swerdlow
Professor of Epidemiology
Institute of Cancer Research Sutton
Benjamin Bitler
Professor
University of Colorado Anschutz Medical Campus
Fulvio Ricceri
University of Turin
Piet van den Brandt
Professor of Epidemiology
University of Maastricht
Martin Widschwendter
Professor; Director
University of Innsbruck
P. M. Webb
Group Leader
QIMR Berghofer Medical Research Institute
Matthew Sikora
Associate Professor
University of Denver
Martin Köbel
Associate Professor
University of Calgary
Shaymaa Bahnassy
Assistant Professor
Georgetown University
Noah Peeri
Assistant Professor
The University of Texas MD Anderson Cancer Center
Rebecca B Riggins
Professor
Georgetown University
Tracy O'Mara
Team Head
QIMR Berghofer Medical Research Institute
James D Brenton
University of Cambridge
Julie R Palmer
Boston University School of Medicine
Leo Schouten
University of Maastricht
Wei Zheng
-
Steffi Oesterreich
UPMC Hillman Cancer Center
Cezary Cybulski
Pomeranian Medical University
Kerry S. Courneya
-
Angela Brooks-Wilson
Simon Fraser University
Tomasz Kluz
Professor
Rzeszów University
Joellen Schilkdraut
Professor
Emory University
Herbert Yu
Researcher/Professor
University of Hawaii at Manoa
Michael Anglesio
Associate Professor
The University of British Columbia
Ramona Erber
W2-Professorin, Oberärztin
University of Regensburg
Usha Menon
Professor of Gynaecological Oncology
University College London
Sandra Orsulic
Professor
University of California, Los Angeles
Cheng-Han Lee
Associate Professor
University of Alberta
Ian Campbell
Group Leader
Peter MacCallum Cancer Institute
Stacey J. Winham
Mayo Clinic College of Medicine and Science
Fabio Parazzini
University of Milan
Michele L. Cote
Indiana University
C Blake Gilks
-
Peter Fasching
-
Rachael Solomon
Senior Eoidemiologist
Division of Cancer Epidemiology and Genetics, National Cancer Institute
Francesmary Modugno
University of Pittsburgh
Alexander Hein
-
Jessica McNeil
Assistant Professor
University of North Carolina at Greensboro
Dale Garsed
University of Melbourne
Renée Fortner
Head of Division
Deutsches Krebsforschungszentrum
K Sundfeldt
Professor/Consultant
University of Gothenburg, Sahlgrenska Academy
Gregg Nelson
Gynecologic Oncologist
University of Calgary
Jo Freudenheim
SUNY Distinguished Professor and Associate Dean
University at Buffalo
Jennifer Anne Doherty
Professor
University of Utah
Anne Zeleniuch-Jacquotte
Professor of Population Health and Environmental Medicine
NYU School of Medicine
Paul Pharoah
Professor of Cancer Epidemiology
Cedars-Sinai Medical Center
Brenda Y Hernandez
University of Hawaii
Eva Negri
Associate professor
University of Bologna
Michael Edwin Jones
Senior Staff Scientist
Institute of Cancer Research
Jan Lubiński
Head of Dept
Pomeranian Medical University
Veronica Setiawan
Associate Professor
University of Southern California
Mona El-Bahrawy
Imperial College London
Zeynep Madak-Erdogan
Professor
University of Illinois at Urbana-Champaign
Aleksandra Gentry-Maharaj
University College London
Susan J. Jordan
Associate Profesor
University of Queensland
Lingeng Lu
Yale School of Public Health
David G. Huntsman
The University of British Columbia
Kimberly A. Bertrand
Associate Professor of Medicine
Boston University
Susan Ramus
Professor of Molecular Oncology
University of New South Wales
Aline Talhouk
Assistant Professor
The University of British Columbia
Make your next move.
Prepare your application
Review drafts before you send them.